Skip to main content

Advertisement

Log in

Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

We assessed the role of the maximum standardized uptake value (SUVmax) of bone marrow and the extramedullary lesion with the highest SUVmax in positron emission tomography/computed tomography (PET/CT) of newly diagnosed multiple myeloma (MM) patients in predicting overall survival (OS).

Methods

A total of 61 newly diagnosed patients (55 MM and 6 plasmacytoma) were enrolled in the study [37 men and 24 women with a median age of 57 years (range 28–80 years)]. The SUVmax of bone marrow and the extramedullary lesion in PET/CT was correlated with the levels of β2-microglobulin, C-reactive protein (CRP), albumin, creatinine, per cent of bone marrow plasma cells, serum free light chain (FLC) ratio, International Staging System (ISS) score and Durie-Salmon stage.

Results

The extramedullary lesion with the highest SUVmax showed significant correlation with bone marrow fluorodeoxyglucose (FDG) uptake (p = 0.027) and near significant correlation with ISS (p = 0.048). Bone marrow SUVmax correlated significantly with the per cent of bone marrow plasma cell count (p = 0.024), CRP (p = 0.012) and ISS (p = 0.013). In stage III MM the mean values of SUVmax in extramedullary lesions were significantly higher than stages I and II (6.23 ± 6.32 vs 2.85 ± 3.44, p = 0.023). The serum FLC ratio did not show any correlation with SUVmax of lesions and bone marrow (p > 0.05). Forty-four MM patients with FDG-positive lesions in PET/CT showed inferior 5-year estimated survival (61.73%) when compared to 11 patients without FDG-positive lesions, all of whom were alive (p = 0.01). In multivariate analysis an extramedullary lesion with the highest SUVmax was the only independent predictor of OS (p = 0.03).

Conclusion

PET/CT allows identification of high-risk myeloma patients, and extramedullary lesions with the highest SUVmax independently predict inferior OS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6–29.

    Article  PubMed  CAS  Google Scholar 

  2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749–57.

    Article  Google Scholar 

  3. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842–54.

    Article  PubMed  CAS  Google Scholar 

  4. Durie BG. The role of anatomic and functional staging in myloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006;42:1539–43.

    Article  PubMed  Google Scholar 

  5. Delorme S, Baur-Melnyk A. Imaging in multiple myeloma. Eur J Radiol 2009;70:401–8.

    Article  PubMed  Google Scholar 

  6. Sasaki M, Ichiya Y, Kuwabara Y, Otsuka M, Fukumura T, Kawai Y, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in technetium-99m-hydroxymethylenediphosphate negative bone tumors. J Nucl Med 1993;34:288–90.

    PubMed  CAS  Google Scholar 

  7. el-Shirbiny AM, Yeung H, Imbriaco M, Michaeli J, Macapinlac H, Larson SM. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med 1997;38:1208–10.

    PubMed  CAS  Google Scholar 

  8. Orchard K, Barrington S, Buscombe J, Hilson A, Prentice HG, Mehta A. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol 2002;117:133–5.

    Article  PubMed  Google Scholar 

  9. Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol 2002;31:690–4.

    Article  PubMed  Google Scholar 

  10. Durie BGM, Waxman AD, D’Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:1457–63.

    PubMed  Google Scholar 

  11. Schirrmeister H, Bommer M, Buck AK, Müller S, Messer P, Bunjes D, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29(3):361–6.

    Article  PubMed  CAS  Google Scholar 

  12. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–23.

    Article  PubMed  Google Scholar 

  13. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009;23:1545–56.

    Article  PubMed  CAS  Google Scholar 

  14. Lütje S, de Rooy JWJ, Croockewit S, Koedam E, Oyen WJG, Raymakers RA. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol 2009;88:1161–8.

    Article  PubMed  Google Scholar 

  15. Mileshkin L, Blum R, Seymour JF, Patrikeos A, Hicks RJ, Prince M. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol 2004;72:32–7.

    Article  PubMed  CAS  Google Scholar 

  16. Schirrmeister H, Buck AK, Bergmann L, Reske SN, Bommer M. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm 2003;18:841–5.

    Article  PubMed  Google Scholar 

  17. Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 2006;33:525–31.

    Article  PubMed  Google Scholar 

  18. Breyer RJ, Mulligan ME, Smith SE, Line BR, Badros AZ. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol 2006;35:632–40.

    Article  PubMed  Google Scholar 

  19. Mulligan ME, Badros AZ. PET/CT and MR imaging in myeloma. Skeletal Radiol 2007;36:5–16.

    Article  PubMed  Google Scholar 

  20. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010;21:325–30.

    Article  PubMed  CAS  Google Scholar 

  21. Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F, et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 2008;49:195–200.

    Article  PubMed  Google Scholar 

  22. Hur J, Yoon CS, Ryu YH, Yun MJ, Suh JS. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma. Acta Radiol 2008;49:427–35.

    Article  PubMed  CAS  Google Scholar 

  23. Dimitrakopoulou-Strauss DA, Hoffmann M, Bergner R, Uppenkamp M, Haberkorn U, Strauss LG. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET. Clin Nucl Med 2009;34:576–84.

    Article  PubMed  Google Scholar 

  24. Bartel TB, Haessler J, Brown LYT, Shaughnessy JD, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009;114:2068–76.

    Article  PubMed  CAS  Google Scholar 

  25. Castellani M, Carletto M, Baldini L, Calori R, Longari V, Soligo D, et al. The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi. Clin Nucl Med 2010;35:1–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mustafa Ünlü.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haznedar, R., Akı, S.Z., Akdemir, Ö.U. et al. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging 38, 1046–1053 (2011). https://doi.org/10.1007/s00259-011-1738-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-011-1738-8

Keywords

Navigation